Ingredient or product comparison
GHK-Cu for Stretch Marks: Clinical Evidence Comparison
Randomized controlled trial (n=20) 2.5% GHK-Cu gel, twice daily, 12 weeks Skin thickness (ultrasound) 31% increase in dermal thickness Demonstrates collagen synthesis is occurring. Not surface hydration Split-abdomen study (n=30) 3% GHK-Cu cream vs vehicle con
This source-based comparison does not add ratings or recommend a winner.
- Randomized controlled trial (n=20)
- 2.5% GHK-Cu gel, twice daily, 12 weeks
- Skin thickness (ultrasound)
- 31% increase in dermal thickness
- Demonstrates collagen synthesis is occurring. Not surface hydration
- Split-abdomen study (n=30)
- 3% GHK-Cu cream vs vehicle control, 16 weeks
- Stretch mark width and pigmentation
- 23% reduction in width, improved pigmentation scores
- Peptide group showed measurable restructuring vs control
- Observational cohort (n=50)
- Subcutaneous GHK-Cu injections, 0.5mg weekly, 8 weeks
- Patient-reported texture improvement
- 68% reported moderate-to-significant improvement
- Injection route delivers higher dermal concentration than topical
- In vitro fibroblast study
- GHK-Cu at 1–10 μM concentrations
- Collagen type I synthesis (ELISA)
- 70% increase at 10 μM
- Establishes dose-dependent response in human dermal fibroblasts